Hologic receives US contract to scale-up Covid-19 test production

2 November 2020 (Last Updated November 2nd, 2020 12:17)

Hologic has secured a $119m contract from the US Government to scale-up its production capacity for molecular tests for Covid-19.

Hologic receives US contract to scale-up Covid-19 test production
The tests run on the Panther Fusion and Panther systems, which deliver initial results in approximately three hours. Credit: Fernando Zhiminaicela / Pixabay.

Hologic has secured a $119m contract from the US Government to scale-up its production capacity for molecular tests for Covid-19.

According to the contract, the company will provide 13 million Covid-19 molecular tests a month to the US by January 2022.

The tests run on the fully automated Panther Fusion and Panther systems, which deliver initial results in approximately three hours and are capable of processing over 1,000 tests in 24 hours.

The US Food and Drug Administration (FDA) granted emergency use authorisation (EUA) for Hologic’s Panther Fusion SARS-CoV-2 Assay and Aptima SARS-CoV-2 Assay in March and May respectively.

Hologic Diagnostic Solutions Division president Kevin Thornal said: “Hologic has already made significant investments in our test production capacity, which have resulted in our contributing tens of millions of Covid tests to the US supply.

“Our manufacturing teams continue to innovate to increase our contribution and we are very pleased to partner with the federal government to further our ability to meet the ongoing public health need.”

The Panther molecular diagnostics system is a sample-to-result platform that can be used in low, medium, or high-throughput laboratories.

Incorporated with small footprint, adaptable workflow options, and consolidated testing menu, the platform merges women’s health, sexually transmitted infections, and viral testing, which can be carried out simultaneously.

Moreover, patient samples can be loaded onto the Panther system as they reach the lab, a capability known as random access that improves efficiency and workflow.

With high throughput and quick turnaround time, the instrument helps to deliver sample results faster.

The Panther Fusion system combines polymerase chain reaction (PCR) chemistry and provides an expanded in vitro diagnostics menu with an open access functionality that helps to run laboratory-developed tests.

The systems offer 16 FDA-cleared assays and 20 CE-marked assays that can detect over 20 pathogens.

As many as 2,000 of these systems have been installed in clinical diagnostic laboratories worldwide with all 50 US states equipped with the systems.